Receiving and Storing the Investigational Product

Part of Clinical Research Coordinator (CRC) Training: Investigational Product at the Site.

About 7 minutes. Free, in your language, no account needed.

Why this matters

Everything else you do in a trial produces a record. This part produces a record and a physical object that goes into a person's body.

The investigational product is the thing being tested. If nobody can show where it was, what temperature it was held at, and who touched it between the sponsor's warehouse and the participant's hand, then nobody can say with confidence what the trial actually tested. A regulator reviewing the results is entitled to ask that question years later, and the only answer available will be your records.

This is also the part of the job most often handed to a coordinator without training, because it looks like receiving a parcel. It is not.

Who is allowed to handle it

E6(R3) §2.10.1 and §2.10.2 put responsibility for investigational product management at the site with the investigator. It may be delegated — to a pharmacist, a nurse, or you — but only to someone qualified to do it, and the investigator still supervises.

In practice that means three things:

• The person receiving, storing and dispensing product is named on the delegation log for that task specifically. "Study procedures" is not enough; product handling is its own line.
• That person has been trained on this protocol's product handling, and the training is documented.
• If your site has a research pharmacy, product almost always goes there. If it does not, the site needs a defined, access-controlled place and a named person, not a cupboard everyone can open.

If you are not on the log for product handling, you do not sign for the shipment. The signature attests that a qualified person checked it.

The receipt check

A shipment arrives. Before it is put away, and ideally before the courier leaves, work through the same sequence every time.

Check the shipment against the paperwork. Kit or bottle numbers, quantities, batch or lot numbers, and expiry dates against the packing list and the shipment notification. Count what is physically there. Do not sign for what you have not counted.

Check the physical condition. Damaged outer packaging, broken seals, crushed blisters, anything that looks wrong. A kit that arrived damaged is not a kit you can dispense.

Read the transit temperature record. Most shipments travel with a monitor or an indicator. Some show a simple in-range or out-of-range result; others download a full trace. Read it before you accept the shipment, not a week later.

Acknowledge receipt in the system. Most trials use an interactive response system — IRT or IWRS — and product is not available to dispense until receipt is confirmed there. An unacknowledged shipment is a common reason a site cannot randomize on the morning it wants to.

File the paperwork. The shipping documents, the temperature record and your receipt record are part of the accountability chain and belong in the site file.

If anything fails these checks, quarantine the affected product rather than storing it as usable stock and tell the sponsor or the monitor the same day. Quarantine means physically separated and clearly marked, so nobody can dispense it while the question is open.

Storage

E6(R3) §2.10.4 and §2.10.5 require the product to be stored as specified by the sponsor and in line with applicable requirements. The specification comes from the protocol and the pharmacy manual, and it is specific to this trial — not to your site's general practice.

What that means day to day:

• Access is controlled and limited to the people on the delegation log for product handling.
• Investigational product is kept separate from routine clinical stock. Trial product is not hospital pharmacy stock and must never be borrowed for a non-trial patient, however urgent.
• Conditions are monitored continuously, not spot-checked. A recording device with minimum and maximum capture, calibrated and in date, with a calibration certificate you can produce.
• Someone reviews the readings on a defined schedule and signs that they did. An unread temperature log is not monitoring.
• Alarms reach a person, including out of hours, and the site knows who responds.

VT-201's tablets are stored at controlled room temperature. That sounds forgiving until a bank holiday weekend, when a store room with a south-facing window and the air handling turned down can sit well above its limit for three days with nobody in the building.

When the temperature goes out of range

A temperature excursion is not, by itself, a disaster. Handling it badly is. The sequence is fixed, and the order matters.

1. Stop dispensing from that location immediately and quarantine the affected product.
2. Capture the data: what the reading was, how far out, for how long, and which kits were in that location for that period.
3. Report it to the sponsor without waiting to see whether it matters. You are not the person who decides whether the product is still usable.
4. Wait for the sponsor's disposition decision. Product stays quarantined until you have it in writing.
5. Document all of it contemporaneously, including the decision and what happened to the affected kits.

The one thing you must never do is decide for yourself that a short excursion was probably fine and carry on dispensing. Stability is a question about the molecule, answered by the sponsor with data you do not have. And if product from that location has already been dispensed, that is a safety matter for the investigator, not something to note quietly in the log.

In practice

Northside Clinic takes a VT-201 shipment on a Friday afternoon. Nadia counts the kits against the packing list and finds twelve where the list says twelve, all with intact seals. The transit indicator reads in range. She acknowledges receipt in the IRT and files the paperwork.

On Tuesday the store room's monitor shows a maximum of 31 °C, reached over the weekend and held for roughly eleven hours. The protocol specifies storage at 15–25 °C.

Nadia quarantines everything in that room, including the new shipment, and stops dispensing from it. She pulls the full temperature trace, lists the kit numbers held there over the weekend, and emails Vantis Pharma the same morning with the trace attached. She tells Dr. Osei, because two participants were dispensed from that room on the Friday.

Vantis replies on Thursday: the excursion is within the product's known stability envelope, the quarantined kits are released, and no action is needed for the two dosed participants. Nadia files the release, returns the kits to usable stock, and records the whole sequence in the site file.

Everything about that outcome was fine. What made it defensible was that the decision came from the sponsor with data, and that the record shows the site stopped first and asked second.

Key takeaways

• Product handling is a delegated task in its own right; be named on the log before you sign for a shipment.
• Check quantities, condition and the transit temperature record before accepting a shipment, and acknowledge receipt in the IRT.
• Store as the protocol specifies, with controlled access, continuous monitoring, calibrated equipment, and someone who actually reads the log.
• On an excursion: quarantine, capture, report, wait for the sponsor's decision, document. Never self-assess stability.
• Investigational product is never borrowed for non-trial patients.